Literature DB >> 26990570

Gene Expression in Biopsies of Acute Rejection and Interstitial Fibrosis/Tubular Atrophy Reveals Highly Shared Mechanisms That Correlate With Worse Long-Term Outcomes.

B D Modena1, S M Kurian1,2, L W Gaber3, J Waalen1, A I Su1, T Gelbart2, T S Mondala2, S R Head2, S Papp2, R Heilman4,5, J J Friedewald6, S M Flechner4,7, C L Marsh4,8, R S Sung4,9, H Shidban4,10, L Chan4,11, M M Abecassis6, D R Salomon1,2,4.   

Abstract

Interstitial fibrosis and tubular atrophy (IFTA) is found in approximately 25% of 1-year biopsies posttransplant. It is known that IFTA correlates with decreased graft survival when histological evidence of inflammation is present. Identifying the mechanistic etiology of IFTA is important to understanding why long-term graft survival has not changed as expected despite improved immunosuppression and dramatically reduced rates of clinical acute rejection (AR) (Services UDoHaH. http://www.ustransplant.org/annual_reports/current/509a_ki.htm). Gene expression profiles of 234 graft biopsy samples were obtained with matching clinical and outcome data. Eighty-one IFTA biopsies were divided into subphenotypes by degree of histological inflammation: IFTA with AR, IFTA with inflammation, and IFTA without inflammation. Samples with AR (n = 54) and normally functioning transplants (TX; n = 99) were used in comparisons. A novel analysis using gene coexpression networks revealed that all IFTA phenotypes were strongly enriched for dysregulated gene pathways and these were shared with the biopsy profiles of AR, including IFTA samples without histological evidence of inflammation. Thus, by molecular profiling we demonstrate that most IFTA samples have ongoing immune-mediated injury or chronic rejection that is more sensitively detected by gene expression profiling. These molecular biopsy profiles correlated with future graft loss in IFTA samples without inflammation. © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Interstitial fibrosis and tubular atrophy; basic (laboratory) research/science; genomics; graft survival; immunobiology; kidney (allograft) function/dysfunction; kidney transplantation/nephrology; organ transplantation in general; rejection: T cell mediated (TCMR); translational research/science

Mesh:

Year:  2016        PMID: 26990570      PMCID: PMC5501990          DOI: 10.1111/ajt.13728

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  63 in total

1.  Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

Authors:  Herwig-Ulf Meier-Kriesche; Jesse D Schold; Titte R Srinivas; Bruce Kaplan
Journal:  Am J Transplant       Date:  2004-03       Impact factor: 8.086

2.  Early loss of renal transcripts in kidney allografts: relationship to the development of histologic lesions and alloimmune effector mechanisms.

Authors:  G Einecke; G Broderick; B Sis; P F Halloran
Journal:  Am J Transplant       Date:  2007-05       Impact factor: 8.086

3.  Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection.

Authors:  Pierre Saint-Mezard; Céline C Berthier; Hai Zhang; Alexandre Hertig; Sergio Kaiser; Martin Schumacher; Grazyna Wieczorek; Marc Bigaud; Jeanne Kehren; Eric Rondeau; Friedrich Raulf; Hans-Peter Marti
Journal:  Transpl Int       Date:  2008-11-06       Impact factor: 3.782

4.  Late acute rejection: incidence, risk factors, and effect on graft survival and function.

Authors:  Loai Eid; Shamir Tuchman; Asha Moudgil
Journal:  Pediatr Transplant       Date:  2013-12-28

5.  Rejection: an integrated response.

Authors:  P W Nickerson; D N Rush
Journal:  Am J Transplant       Date:  2013-08-01       Impact factor: 8.086

6.  Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients.

Authors:  Philip F Halloran; Jessica Chang; Konrad Famulski; Luis G Hidalgo; Israel D R Salazar; Maribel Merino Lopez; Arthur Matas; Michael Picton; Declan de Freitas; Jonathan Bromberg; Daniel Serón; Joana Sellarés; Gunilla Einecke; Jeff Reeve
Journal:  J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 10.121

7.  Predicting subsequent decline in kidney allograft function from early surveillance biopsies.

Authors:  Fernando G Cosio; Joseph P Grande; Hani Wadei; Timothy S Larson; Matthew D Griffin; Mark D Stegall
Journal:  Am J Transplant       Date:  2005-10       Impact factor: 8.086

8.  Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG).

Authors:  Ingeborg A Hauser; Sandra Spiegler; Eva Kiss; Stefan Gauer; Olaf Sichler; Ernst H Scheuermann; Hanns Ackermann; Josef M Pfeilschifter; Helmut Geiger; Hermann-Josef Gröne; Heinfried H Radeke
Journal:  J Am Soc Nephrol       Date:  2005-04-27       Impact factor: 10.121

9.  Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients.

Authors:  R L Heilman; Y Devarapalli; H A Chakkera; K L Mekeel; A A Moss; D C Mulligan; M J Mazur; K Hamawi; J W Williams; K S Reddy
Journal:  Am J Transplant       Date:  2010-02-01       Impact factor: 8.086

10.  Chemokine expression in renal ischemia/reperfusion injury is most profound during the reparative phase.

Authors:  Ingrid Stroo; Geurt Stokman; Gwen J D Teske; Anje Raven; Loes M Butter; Sandrine Florquin; Jaklien C Leemans
Journal:  Int Immunol       Date:  2010-04-21       Impact factor: 4.823

View more
  33 in total

Review 1.  Biomarkers to detect rejection after kidney transplantation.

Authors:  Vikas R Dharnidharka; Andrew Malone
Journal:  Pediatr Nephrol       Date:  2017-06-19       Impact factor: 3.714

Review 2.  Moving Biomarkers toward Clinical Implementation in Kidney Transplantation.

Authors:  Madhav C Menon; Barbara Murphy; Peter S Heeger
Journal:  J Am Soc Nephrol       Date:  2017-01-06       Impact factor: 10.121

3.  Discovery and cross-validation of peripheral blood and renal biopsy gene expression signatures from ethnically diverse kidney transplant populations.

Authors:  Carlucci G Ventura; Thomas Whisenant; Terri Gelbart; Daisa S R David; Fabiana Agena; Daniel R Salomon; Elias David-Neto; Sunil M Kurian
Journal:  Am J Transplant       Date:  2019-07-08       Impact factor: 8.086

4.  Transplantation: Utilizing the transcriptome to predict allograft fibrosis.

Authors:  Adyr Moss; Bruce Kaplan
Journal:  Nat Rev Nephrol       Date:  2016-09-19       Impact factor: 28.314

Review 5.  Current status of alloimmunity.

Authors:  Thiago J Borges; Naoka Murakami; Leonardo V Riella
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-11       Impact factor: 2.894

6.  Inflammatory macrophage-associated 3-gene signature predicts subclinical allograft injury and graft survival.

Authors:  Tej D Azad; Michele Donato; Line Heylen; Andrew B Liu; Shai S Shen-Orr; Timothy E Sweeney; Jonathan Scott Maltzman; Maarten Naesens; Purvesh Khatri
Journal:  JCI Insight       Date:  2018-01-25

7.  B Cell Recruitment Follows Kidney Injury and Maladaptive Repair.

Authors:  Anita S Chong
Journal:  Transplantation       Date:  2019-08       Impact factor: 4.939

Review 8.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

9.  Orthogonal Comparison of Molecular Signatures of Kidney Transplants With Subclinical and Clinical Acute Rejection: Equivalent Performance Is Agnostic to Both Technology and Platform.

Authors:  S M Kurian; E Velazquez; R Thompson; T Whisenant; S Rose; N Riley; F Harrison; T Gelbart; J J Friedewald; J Charette; S Brietigam; J Peysakhovich; M R First; M M Abecassis; D R Salomon
Journal:  Am J Transplant       Date:  2017-04-03       Impact factor: 8.086

Review 10.  Molecular assessment of disease states in kidney transplant biopsy samples.

Authors:  Philip F Halloran; Konrad S Famulski; Jeff Reeve
Journal:  Nat Rev Nephrol       Date:  2016-06-27       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.